Evidence map›Paper›PMID 32424201›Full record

ReviewHypertension research : official journal of the Japanese Society of Hypertension2020

Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.

Satoshi Morimoto, Atsuhiro Ichihara

Abstract readReview
PubMed Publisher
In one paragraph

Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Metabolic and body composition shifts after adrenalectomy in unilateral primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  2. Article
  3. Aldosterone breakthrough from a pharmacological perspective.Hypertension research : official journal of the Japanese Society of Hypertension · 2022
    Review
  4. Lysine-specific demethylase 1 as a corepressor of mineralocorticoid receptor.Hypertension research : official journal of the Japanese Society of Hypertension · 2022
    Article
  5. Article
  6. Article
  7. DNA Methylation of the Angiotensinogen Gene,International journal of molecular sciences · 2021
    Review
  8. Practice Recommendations for Diagnosis and Treatment of the Most Common Forms of Secondary Hypertension.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2020
    Review
  9. Hypothalamus-pituitary-adrenal Axis in Glucolipid metabolic disorders.Reviews in endocrine & metabolic disorders · 2020
    Review
  10. The renin angiotensin aldosterone system and COVID-19.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Satoshi MorimotoDepartment of Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan. morimoto.satoshi@twmu.ac.jp.
Atsuhiro IchiharaDepartment of Endocrinology and Hypertension, Tokyo Women's Medical University, Tokyo, Japan.
Tokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistant hypertension is associated with a poor prognosis due to organ damage caused by prolonged suboptimal blood pressure control. The concomitant use of mineralocorticoid receptor (MR) antagonists with other antihypertensives has been shown to improve blood pressure control in some patients with resistant hypertension, and such patients are considered to have MR-associated hypertension. MR-associated hypertension is classified into two subtypes: one with a high plasma aldosterone level, which includes primary aldosteronism (PA), and the other with a normal aldosterone level. In patients with unilateral PA, adrenalectomy may be the first-choice procedure, while in patients with bilateral PA, MR antagonists are selected. In addition, in patients with other types of MR-associated hypertension with high aldosterone levels, MR antagonists may be selected as a first-line therapy. In patients with normal aldosterone levels, ARBs or ACE inhibitors are used as a first-line therapy, and MR antagonists may be used as an add-on agent. Since MR antagonist therapy may have efficacy as a first-line or add-on agent in these patients, it is important to recognize this type of hypertension. Further studies are needed to elucidate the pathogenesis and management of MR-associated hypertension in more detail to improve the clinical outcomes of patients with MR-associated hypertension.

Indexed as

AdrenalectomyAntihypertensive AgentsDisease ManagementHumansHyperaldosteronismHypertensionMineralocorticoid Receptor AntagonistsAntihypertensive AgentsMineralocorticoid Receptor AntagonistsAldosteroneAngiotensin-converting enzymeAngiotensin receptor blockerMineralocorticoid receptor antagonistResistant hypertension

Identifiers

PMID32424201
OpenAlexW3024664551

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.